|
Dr. Gordeev has been one of the scientific founders of Vicuron Pharmaceuticals Inc. (formerly Versicor Inc.). His industrial and academic career spans over 22 years. In recent years, he has served as Vice President of Chemistry of Vicuron, where Dr. Gordeev has led several successful drug discovery programs, both internal and that in collaboration with Novartis and Pfizer (which subsequently acquired Vicuron). This work has resulted in the identification of several clinical compounds, including the best-in-class lincosamides, oxazolidinones, and first-in-class PDF inhibitors. As a member of the global Vicuron IND team, Dr. Gordeev also managed pre-clinical chemistry in support of the corporate development team. Prior to Vicuron, he has led groups of GlaxoWellcome and Affymax scientists in a pioneering research on the application of combinatorial chemistry in multiple medicinal chemistry programs. Prior to his USA biopharma experience, Dr. Gordeev has held a sr. scientist position at the Zelinsky Institute of Organic Chemistry of the Russian Academy of Sciences (Moscow), and then served as a group leader at the Prof. Katritzky's Center for Heterocyclic Compounds (Univ. of Florida, Gainesville). He received his M.S. and Ph.D. degrees in Organic Chemistry from the Moscow State University (Moscow, Russia). Dr. Gordeev has authored in excess of 100 scientific publications and patents in areas of medicinal, bioorganic, and synthetic chemistry. | 